Werfen

Werfen Receives US FDA 510(K) Clearance for Aptiva® Connective Tissue Disease Essential Reagent

Retrieved on: 
Monday, October 16, 2023
Autoimmune disease, Werfen, Doctor of Philosophy, PMAT, Health, Business, CTD, Connective tissue disease, Medical imaging, Fine chemical, IBM Aptiva, Research, Diagnosis

SAN DIEGO, Oct. 16, 2023 /PRNewswire/ -- Werfen today announced 510(k) clearance of Aptiva® Connective Tissue Disease (CTD) Essential reagent by the US Food and Drug Administration (FDA).

Key Points: 
  • New Reagent Aids in Diagnosis of Connective Tissue Disease in Hard-to-Diagnose Autoimmune Diseases, Reducing Time to Diagnosis and Improving Patient Outcomes
    The Aptiva CTD Essential complements Werfen's previously cleared Aptiva Celiac Disease reagent.
  • In addition to CTD and Celiac Disease assays, Aptiva will target additional autoimmune disease states, and has over 60 analytes in various stages of advanced development.
  • "We are excited to bring this latest expansion of the Aptiva reagent menu to the US market, resulting in advanced patient care."
  • PMAT enables Aptiva CTD Essential reagent to deliver up to 600 results per hour and allows the laboratory to complete its test volume with minimal hands-on time.

Launch of We Venture Capital

Retrieved on: 
Thursday, September 7, 2023
Biotechnology, Venture capital, Growth, Health, Investment, Series A round, Capital, Renewable energy, Werfen

BARCELONA, Spain, Sept. 7, 2023 /PRNewswire/ -- We Venture Capital, the corporate venture capital operation of Werfen, announces its launch today.

Key Points: 
  • BARCELONA, Spain, Sept. 7, 2023 /PRNewswire/ -- We Venture Capital, the corporate venture capital operation of Werfen, announces its launch today.
  • We Venture Capital is the venture capital arm of Werfen committed to investing in diagnostics start-ups, as well as digital solutions and biotechnology, surrounding the diagnostics space.
  • Through a global reach, We Venture Capital invests primarily in Series A, and may also invest in Seed or Series B.
  • We want to thank everyone who has supported this launch and for bringing We Venture Capital to life."

Launch of We Venture Capital

Retrieved on: 
Thursday, September 7, 2023
Biotechnology, Venture capital, NN, Growth, Health, Investment, Series A round, Capital, Renewable energy, Venture, Werfen

BARCELONA, Spain, Sept. 7, 2023 /PRNewswire/ -- We Venture Capital, the corporate venture capital operation of Werfen, announces its launch today.

Key Points: 
  • BARCELONA, Spain, Sept. 7, 2023 /PRNewswire/ -- We Venture Capital, the corporate venture capital operation of Werfen, announces its launch today.
  • We Venture Capital is the Venture capital arm of Werfen committed to investing in diagnostics start-ups, as well as digital solutions and biotechnology, surrounding the diagnostics space.
  • Through a global reach, We Venture Capital invests primarily in Series A, and may also invest in Seed or Series B.
  • We want to thank everyone who has supported this launch and bringing We Venture Capital to life."

Seegene and Werfen Partner to Collaborate on OneSystem™ Business to Develop Syndromic qPCR Assays

Retrieved on: 
Wednesday, June 14, 2023
Human, Partnership, Cancer, Infection, Multimedia, Drug resistance, Real-time, Pandemic, Werfen, OEM, PCR, Pharmaceutical industry

The collaboration will consist of the joint development of syndromic qPCR assays suitable for the Spanish and Portuguese healthcare systems, including assays for sexually transmitted infections and drug resistance.

Key Points: 
  • The collaboration will consist of the joint development of syndromic qPCR assays suitable for the Spanish and Portuguese healthcare systems, including assays for sexually transmitted infections and drug resistance.
  • The companies are discussing the co-development of qPCR assays at Werfen's OEM Technology Center in Lliçà d´Amunt, Barcelona, Spain.
  • Seegene's OneSystem™ Business aims to share: its syndromic quantitative PCR technologies, and Seegene's digitalized development system (SGDDS) which enables less experienced researchers to develop assays.
  • "We will share our PCR technologies and know-how with any company in any country wishing to develop syndromic quantitative PCR assays," said Dr. Jong-Yoon Chun, CEO of Seegene.

Seegene and Werfen Partner to Collaborate on OneSystem™ Business to Develop Syndromic qPCR Assays

Retrieved on: 
Wednesday, June 14, 2023
Human, Partnership, Cancer, Infection, Drug resistance, Real-time, Pandemic, Werfen, OEM, PCR, Pharmaceutical industry

The collaboration will consist of the joint development of syndromic qPCR assays suitable for the Spanish and Portuguese healthcare systems, including assays for sexually transmitted infections and drug resistance.

Key Points: 
  • The collaboration will consist of the joint development of syndromic qPCR assays suitable for the Spanish and Portuguese healthcare systems, including assays for sexually transmitted infections and drug resistance.
  • The companies are discussing the co-development of qPCR assays at Werfen's OEM Technology Center in Lliçà d´Amunt, Barcelona, Spain.
  • Seegene's OneSystem™ Business aims to share: its syndromic quantitative PCR technologies, and Seegene's digitalized development system (SGDDS) which enables less experienced researchers to develop assays.
  • "We will share our PCR technologies and know-how with any company in any country wishing to develop syndromic quantitative PCR assays," said Dr. Jong-Yoon Chun, CEO of Seegene.

WERFEN SIGNS LONG-TERM, EXCLUSIVE WORLDWIDE DISTRIBUTOR AGREEMENT WITH THERMO FISHER SCIENTIFIC FOR HEMOSTASIS TESTING WORKCELL

Retrieved on: 
Thursday, May 4, 2023
Partnership, Workflow, Thermo Fisher Scientific, STAT, Laboratory, ACL, Safety, Medical device, Fine chemical, Werfen, Hemostasis

BEDFORD, Mass., May 4, 2023 /PRNewswire/ -- Werfen today announced they have signed a new long-term, exclusive partnership agreement with Thermo Fisher Scientific, for worldwide distribution of TCAutomation laboratory automation system, in the specialized field of Hemostasis Diagnostics. Following their previous exclusive agreement, signed in 2015, this allows Werfen to continue offering HemoCell Specialized Lab Automation, with the largest installed base of Hemostasis automation workcells globally.

Key Points: 
  • BEDFORD, Mass., May 4, 2023 /PRNewswire/ -- Werfen today announced they have signed a new long-term, exclusive partnership agreement with Thermo Fisher Scientific, for worldwide distribution of TCAutomation laboratory automation system, in the specialized field of Hemostasis Diagnostics.
  • Following their previous exclusive agreement, signed in 2015, this allows Werfen to continue offering HemoCell Specialized Lab Automation, with the largest installed base of Hemostasis automation workcells globally.
  • "This significant continuation of our long-term distribution agreement is a testament to the strength of our partnership with Thermo Fisher Scientific," said Remo Tazzi, Vice President, Worldwide Marketing and Service, Hemostasis and Acute Care Diagnostics at Werfen.
  • HemoHub™ Intelligent Data Manager centralizes management of Hemostasis testing  and intelligent sample routing with real-time adaptations and queue balancing.

Werfen Receives 2022 IMV ServiceTrak Awards for Best Customer Satisfaction and Best Service in Hemostasis and Blood Gas

Retrieved on: 
Wednesday, January 4, 2023
Hemostasis, Original equipment manufacturer, GEM, CO-oximeter, ACL, NOVA, Chrysler, Strategic planning, Autoloader, Name, ACD, Blood, Catheter, Patent, Automation, Thrombosis, Agilent ChemStation, IBM Aptiva, Originality, Data management, Hospital, High-dependency unit, Health care, Accreditation, Coagulopathy, Information technology, OEM, Commercial Operating System (COS), POC, IMV, Pharmaceutical industry, Medical device, Medical imaging, Science, Autoimmunity, Werfen, Coagulation

BEDFORD, Mass., Jan. 4, 2023 /PRNewswire/ -- Werfen today announced that it has received five 2022 IMV ServiceTrak Awards including Best System Performance and Best Service in the Coagulation (Hemostasis) category, as well as Best Customer Satisfaction, Best System Performance and Best Service in the Blood Gas category.

Key Points: 
  • BEDFORD, Mass., Jan. 4, 2023 /PRNewswire/ -- Werfen today announced that it has received five 2022 IMV ServiceTrak Awards including Best System Performance and Best Service in the Coagulation (Hemostasis) category, as well as Best Customer Satisfaction, Best System Performance and Best Service in the Blood Gas category.
  • IMV ServiceTrak 2022 Clinical Laboratory Awards are presented to manufacturers whose customers are highly satisfied with their products and services.
  • Results are based on interviews conducted with respondents in 1,716 clinical testing locations in the US, representing 2,169 instruments.
  • "It's an incredible honor to have the quality of our products and customer service, in both our Hemostasis and Acute Care Diagnostics business lines, recognized among the winners of the 2022 IMV awards," said Bill Crandell, Vice President of Commercial Operations, North America at Werfen.

WERFEN ANNOUNCES WORLDWIDE COMMERCIAL RELEASE OF GEMWEB® LIVE REAL-TIME ONSCREEN VIEWER

Retrieved on: 
Monday, July 25, 2022
IBM Aptiva, Blood, Chrysler, POC, Company, Clopidogrel, Originality, GEM, Heparin, OEM, Elective surgery, Sigma, Solution, Compliance, ACD, Hemostasis, Patent, Agilent ChemStation, CO-oximeter, Data management, Name, Time, Catheter, ACL, Hospital, Health, Hemorheology, High-dependency unit, Autoloader, Efficiency, Original equipment manufacturer, Accreditation, Medical device, Medical imaging, Werfen, Autoimmunity

BEDFORD, Mass., July 25, 2022 /PRNewswire/ -- Werfen today announced the worldwide commercial release of GEMweb Live, a real-time onscreen viewer of diagnostic test results for cardiac surgical procedures. Comprehensive, rapid test results are viewed in real-time on one screen, designed to help guide goal-directed therapy and other critical needs—before, during and after surgery.

Key Points: 
  • BEDFORD, Mass., July 25, 2022 /PRNewswire/ -- Werfen today announced the worldwide commercial release of GEMweb Live, a real-time onscreen viewer of diagnostic test results for cardiac surgical procedures.
  • A digital solution, GEMweb Live coordinates care, enabling time-critical clinical decisions in the cardiovascular operating room (CVOR) by displaying consolidated results.
  • Now, GEMweb Live delivers real-time results throughout a cardiac procedure in one glance.
  • A multidisciplinary approach to patient management, GEMweb Live supports operational efficiency during time-sensitive procedures such as cardiac surgery.

WERFEN RECEIVES US FDA 510(K) CLEARANCE FOR ROTEM SIGMA THROMBOELASTOMETRY SYSTEM

Retrieved on: 
Monday, July 18, 2022
Anesthesiology, Coagulopathy, Solution, Hospital, CO-oximeter, PBM, Paola Lattus, Blood, Multimedia, Company, Efficiency, Bleeding, Health, Sigma, Patient safety, Compliance, Name, Accreditation, Decision-making, Program, Ranitidine bismuth citrate, Hemostasis, Liver transplantation, Surgeon, Originality, View, Autoloader, GEM, Original equipment manufacturer, POC, US Foods, Data management, VP, Critical, Heparin, OEM, Goal, Catheter, IBM Aptiva, High-dependency unit, Chrysler, FDA, ACL, ACD, Agilent ChemStation, Patent, Birth control, Medical device, Medical imaging, A5, Autoimmunity, Werfen

BEDFORD, Mass., July 18, 2022 /PRNewswire/ -- Werfen today announced the 510(k) clearance of the ROTEM sigma Thromboelastometry System by the US Food and Drug Administration (FDA). The ROTEM sigma delivers real-time, rapid and actionable results, now at the point of care (POC), to guide bleeding management. With clinical use throughout Europe, Australia, Asia, Latin America and Africa, the ROTEM sigma will be commercialized in the US in late 2022.

Key Points: 
  • The ROTEM sigma delivers real-time, rapid and actionable results, now at the point of care (POC), to guide bleeding management.
  • Built upon proven cup-and-pin technology, the ROTEM sigma leverages similar assays as its leading predecessor, the ROTEM delta Thromboelastometry System, used widely throughout North America and in thousands of peer-reviewed clinical studies.
  • For a clear picture of coagulopathy, the ROTEM sigma provides at-a-glance assessment of clot firmness and stability, enabling hemostasis optimization, while minimizing blood loss.
  • Additionally, GEMweb Plus 500 Custom Connectivity provides centralized access to results from any networked Werfen ACD system, including ROTEM sigma.

WERFEN AWARDED 2021 IMV SERVICETRAK AWARDS FOR BEST SYSTEM PERFORMANCE AND SERVICE

Retrieved on: 
Monday, March 28, 2022
Data management, IBM Aptiva, Research, Coagulation, Hospital, OEM, SR, Originality, Autoloader, ACD, Chrysler, View, Strategic planning, Commercial Operating System (COS), Multimedia, Thrombosis, ACL, Agilent ChemStation, Name, Health, Company, GEM, Hemostasis, Information management, Automation, Original equipment manufacturer, Coagulopathy, Patent, IMV, Medical device, Science, Autoimmunity, Werfen

BEDFORD, Mass., March 28, 2022 /PRNewswire/ --Werfen has received two IMV ServiceTrak Awards for 2021, including Best System Performance, for the third consecutive year, and Best Service in the Coagulation category, for the second consecutive year.

Key Points: 
  • BEDFORD, Mass., March 28, 2022 /PRNewswire/ --Werfen has received two IMV ServiceTrak Awards for 2021, including Best System Performance, for the third consecutive year, and Best Service in the Coagulation category, for the second consecutive year.
  • IMV ServiceTrak 2021 Clinical Laboratory Awards are presented to manufacturers whose customers are highly satisfied with their products and services.
  • "The entire Werfen team is honored to be recognized yet again through these IMV awards.
  • To receive not only, best system performance but also best service is reflective of the mission we set out on every day, providing the best quality product, so customers can provide the best patient care" said Brian Durkin, Sr. Vice President of Commercial Operations at Werfen North America.